Deliver diagnostic confidence
Anatomic pathology

Deliver diagnostic confidence

Creating an impact on treatment success

 

Base your diagnosis on a fully validated and integrated value chain. Discover our comprehensive portfolio of solutions — from staining to assays to digital pathology.

Diagnosing invasive breast cancer

 

Our comprehensive portfolio offers multiple tests that help determine the right treatment for each patient. HER2 testing for instance, can be used to inform treatment decisions – and this has already supported a 37% relative improvement in the overall survival rate of women with HER2-positive breast cancer.1

Diagnosing invasive breast cancer

Staining

 

Our integrated pathology instruments, clinically significant assays, and digital tools help increase diagnostic certainty and optimize medical value for every patient.

Get in touch

VENTANA HE 600 System
VENTANA HE 600

 

The only automated H&E system with individual slide-staining technology. Designed to improve your workflow, the staining quality, and safety for both patients and technicians.

Learn more

VENTANA BenchMark ULTRA

 

This fully automated instrument offers 30 independent slide drawers and a singlepiece workflow – supporting the largest menu of 250+ ready-to-use assays. 

Learn more

BenchMark ULTRA IHC/ISH System

Comprehensive portfolio of assays

 

Our extensive portfolio consists of robust and highly sensitive assays for breast cancer diagnostics – ready-to-use and of high medical value.2-5

Get in touch

HER2 DD-ISH
HER2 DD-ISH

 

The new VENTANA HER2 Dual ISH DNA Probe Cocktail assay helps identify breast and gastric cancer patients eligible for treatment with HER2-targeted personalized therapies.

Learn more

ER (SP1)
ER (SP1)

 

ER (SP1) antibody has shown the most consistent performance and superior quality when compared to other ER-clones.

Learn more

PR (1E2)
PR (1E2)

 

The PR (1E2) antibody provides significant value as a prognostic factor and response prediction of hormone therapy, even in ER-negative patients.

Learn more

Ki67 (30-9)
Ki-67

 

Staining for Ki-67 can be used to aid in assessing the proliferative activity of normal and neoplastic tissue and can help deliver a confident assessment of tumor aggressiveness.

Learn more

HER2 (4B5)
HER2 (4B5)

 

CE IVD marked assay, indicated as an aid in the assessment of patients with breast or stomach cancer, for whom Herceptin treatment is considered.

Learn more

PD-L1 (SP142) in TNBC
PD-L1 (SP142) in TNBC

 

The SP142 assay is the approved diagnostic test used to identify mTNBC patients most likely to benefit from the addition of atezolizumab to Nab-Paclitaxel.

Learn more


Integrated digital pathology

 

Our digital solutions enable precision diagnosis in support of better, more personalized healthcare.

Get in touch

VENTANA DP 200

 

Our solution enables you to:

  • Accelerate your workflow with anytime / anywhere access
  • Accommodate and streamline collaboration
  • Make precise, accurate diagnoses for your patients

Learn more

VENTANA DP 200 slide scanner
uPath software
uPath software

 

uPath can help you streamline communication and efficiency in the lab: this efficient and sustainable digital pathology solution provides users quick and easy access to the information they need.

Learn more

uPath image analysis

 

Intelligent and insightful digital pathology image analysis algorithms that empower pathologists to confidently, accurately, and objectively assess whole tissue slide images.

Learn more

uPath HER2 Dual ISH Bildanalyse, Brust (CE-IVD)

Get in touch


Would you like to know more about our integrated solutions, or do you have other questions? Leave your details and we will get in touch with you.

Matthias Bodmer

Matthias Bodmer

Disease Area Manager Oncology

Erfolg
Formular erfolgreich abgesendet
text

  1. Perez, E.A., et al. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. J Clin Oncol, 2014. 20(32): pg. 3744-3752.
  2. Mayr et al. Chromogenic in situ hybridization for HER-2/neu-oncogene in breast cancer: comparison of a new dual color chromogenic Histopathology. Dec; 55(6):716-23, 2009
  3. Loftin IR, et al. The INFORM HER2 Dual ISH assay compared with FISH to determine HER2 gene status in invasive breast carcinoma. J Clin Oncol, 29 (suppl 27; abstr 25), 2011
  4. Powell, et al. A new rabbit monoclonal (4B5) antibody for the immunohistochemical (IHC) determination of HER2 status in breast cancer Appl Immunohistochem Mol Morphol, Mar; 15(1):94-102, 2007
  5. Welsh et al. Quantitative analysis of ER expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol 21(2):139147.